CD34 and glioblastoma: Similar to our findings, Cho et al. demonstrated that BCAT1 silencing inhibited the expression of CD34 and HIF-1α, proving the antiangiogenic role of BCAT1 in patients with glioblastoma (Cho et al., 2016).